Skip to content
Open access

EPIC-A: Phase II Trial of Cemiplimab Plus Standard-of-Care Chemotherapy Followed by Maintenance Cemiplimab in Locally Advanced or Metastatic Penile Carcinoma

Oct 2026 · JCO Oncology Advances · 0 citations · 37 references

Abstract

Cisplatin-based combination chemotherapy is standard of care (SoC) for patients with locally advanced/metastatic penile cancer (la/mPC). We evaluated efficacy and safety of cemiplimab plus SoC chemotherapy as first-line treatment in these patients. In this phase II, single-arm, multicenter trial, patients with la/mPC (M 1 ; T any ,N 2-3 ,M 0 ; T 4 ,N any ,M 0 ; T 3 ,N 1 ,M 0 ) not eligible for radical treatment received four cycles of once every 3 weeks cemiplimab 350 mg IV D1 plus SoC chemotherapy: cisplatin/5-fluorouracil (5-FU; 27 patients) or paclitaxel/ifosfamide/cisplatin (two patients), followed by cemiplimab alone, for a maximum of 34 cycles. The primary end point was investigator-assessed clinical benefit rate (CBR) at 12 weeks, evaluated using RECIST 1.1. Twenty-nine patients from 11 UK sites were enrolled from January 2022 to December 2023. Median age was 61 years (range, 38-76). 93% had an Eastern Cooperative Oncology Group performance score of 0-1, and 86.2% had metastatic disease (lung 72.5%, bone 32%, and liver 8%). Median cycle number was 5 (range, 1-34) and median follow-up was 15 (IQR, 6.2-24) months. At 12 weeks, CBR was 62.1% (95% CI, 44.4 to 79.7). Median progression-free survival (PFS) and overall survival (OS) were 6.3 (95% CI, 3.7 to 8.7) and 15.7 (95% CI, 6.3 to 20.0) months, respectively. Correlation between p16 status and response was nonsignificant. Adverse events (AEs) of any grade related to cemiplimab or chemotherapy were 20.4% (67/328) and 43.2% (142/328), respectively. AEs ≥ grade 3 were 10.4% (7/67) and 14.8% (21/142), respectively, with two grade-5 AEs, neither related to cemiplimab but one related to chemotherapy. AE-led discontinuation was 34.6% (9/26) and 54.5% (6/11) for cemiplimab and chemotherapy, respectively. The EPIC-A trial demonstrates the efficacy and safety profile of cemiplimab in combination with cisplatin-based chemotherapy (5-FU and cisplatin, or paclitaxel, ifosfamide, and cisplatin) as a potential treatment for la/mPC. These data suggest that this combination may be a first-line SoC treatment option in this rare cancer.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.